Abstract
Studies have shown that phosphatidylinositol (PI) can stimulate reverse cholesterol transport by enhancing the flux of cholesterol into HDL and by promoting the transport of high density lipoprotein-cholesterol (HDL-C) to the liver and bile. The goal of this study was to determine the safety and therapeutic value of PI after oral administration to normolipidemic human subjects. We performed a randomized 2 week study in 16 normolipidemic subjects. Subjects received either 2.8 or 5.6 g of PI, with or without food. PI was well tolerated by all subjects. PI significantly affected the levels of HDL-C and triglyceride in the plasma of subjects receiving PI with food. The lower dose showed a 13% increase in HDL-C, whereas the high dose showed an increase of 18% over the 2 week period. Both low- and high-dose groups showed significant increases in plasma apolipoprotein A-I. The high dose of PI also decreased plasma triglycerides by 36% in the fed subjects. These data suggest that after only 2 weeks, PI may have a comparable therapeutic value to niacin, with negligible side effects.
Highlights
Studies have shown that phosphatidylinositol (PI) can stimulate reverse cholesterol transport by enhancing the flux of cholesterol into HDL and by promoting the transport of high density lipoprotein-cholesterol (HDL-C) to the liver and bile
Novel HDL therapeutic strategies are under development, and recent reports suggest that the cholesteryl ester transfer protein (CETP) inhibitors, Torcetrapib and JTT-705, may be promising new therapies for increasing HDL-C levels and treating coronary artery disease (CAD) [6, 7]
It is becoming increasingly evident that low HDL-C can be an independent risk predictor of CAD even when low density lipoprotein-cholesterol (LDL-C) is low [17]
Summary
Studies have shown that phosphatidylinositol (PI) can stimulate reverse cholesterol transport by enhancing the flux of cholesterol into HDL and by promoting the transport of high density lipoprotein-cholesterol (HDL-C) to the liver and bile. PI significantly affected the levels of HDL-C and triglyceride in the plasma of subjects receiving PI with food. The high dose of PI decreased plasma triglycerides by 36% in the fed subjects These data suggest that after only 2 weeks, PI may have a comparable therapeutic value to niacin, with negligible side effects.—Burgess, J. Prolonged oral administration of soy lecithin at doses ranging from 12 to 48 g per day have resulted in significant reductions in serum cholesterol and triglyceride levels [9, 10] and increased HDL-C levels [9]. Oral administration of purified soy phosphatidylcholine has been shown to significantly decrease low density lipoprotein-cholesterol (LDL-C) and triglycerides [11, 12] but to have minimal effect on HDL-C [12,13,14].
Sign-in/Register to view highlights & summary 
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
